Algemene informatie
| Vakcode | AM_470718 |
|---|---|
| Studiepunten | 6 EC |
| Periode | P2 |
| Vakniveau | 500 |
| Onderwijstaal | Engels |
| Faculteit | Faculteit der Bètawetenschappen |
| Vakcoördinator | dr. M.M.M. Wilhelmus |
| Examinator | dr. M.M.M. Wilhelmus |
| Docenten |
dr. M.M.M. Wilhelmus |
|
Onderdeel van opleiding(en)
Master
Gebruik pijltjestoetsen om door de lijst te navigeren, Enter om te selecteren, en Escape om te sluiten.
|
|
Praktische informatie
Voor dit vak moet je zelf intekenen. De inteken- en afmeldtermijnen staan op VU.nl
Voor dit vak geldt een maximum aantal deelnemers van 38.
| Onderwijsvorm | Deeltentamen schriftelijk, Hoorcollege |
|---|
Doelgroepen
Dit vak is ook toegankelijk als:
Dit vak wordt in het Engels aangeboden. Omschrijvingen kunnen daardoor mogelijk alleen in het Engels worden weergegeven.
Doel vak
Principal aim of the course is to provide the student with sufficientinsight into the basic principles of Neuro- and Psychopharmacology, in
order to enable the student to independently formulate ideas and
concepts which may lead to the development of innovative drug therapies.
The subjects of the course are largely drawn from research themes of the
Neuroscience Campus Amsterdam of the Vrije Universiteit and VU
University Medical Center.
Specific aims:
A) Students are able to describe the pathology of the disease and
know which biological mechanisms are the driving forces underlying the
pathology.
B) Students are capable of pinpointing possible therapeutic entries
of the disease, and can argue whether and how the therapy will affect
these therapeutic entries.
C) Students are able to defend and motivate their therapeutic
strategy in front of fellow students and teachers.
Inhoud vak
Current pharmacotherapy of well known neurologic- and psychiatricdisorders is based on the use of drugs of which the development has
been guided by, often unproven, hypotheses concerning the
pathophysiology of these diseases. As a result, despite a few "success
stories", in most cases this has led to the introduction of
suboptimally effective compounds. Moreover, these "therapeutics" do not
cure the disease, but merely act to ameliorate the symptoms. However,
in light of the increasing knowledge concerning the pathogenesis of
brain disorders, it now seems highly feasible that in the near future
drugs will be developed which will target the core of the disease
process.
During the course, a small number of lectures will provide the student
with detailed knowledge and insight into the hypotheses that have
guided the development of the current generation of neuro- and
psychopharmaceuticals. Subsequently, the student will be expected to 1)
independently identify the strong points and weaknesses of these
hypotheses, and 2) use the conclusions of this evaluation, in
combination with recent developments in the field, to formulate a well-
based proposal for the development of a new pharmacotherapy for a
specific brain disease.
Aanvullende informatie onderwijsvormen
Lectures (approximately 20h), progression meeting with supervisor(approximately 3h),
'defend your idea' presentation, writing a thesis and preparing final
presentation (approximately 96h). In
total, the students are expected to invest a workload of 20 hour each
week during this course.
Toetsvorm
Pharmacology assignment (15% of mark, in writing), writing (50% of mark)and
public presentation (35% of mark) of thesis.
Vereiste voorkennis
Medical Pharmacology course or equivalent.Literatuur
- Teaching Resource Centre Pharmacology (TRC app available free in theApp store or Itunes, or via Google Play for Android)
- Additional texts provided during the course
Overige informatie
A maximum of 24 students can be accommodated in the course. Preferenceis given to students who participate in the Master of Neuroscience
program of the VU University Amsterdam. Course is taught in English.
For further information please contact dr. M. Wilhelmus
(m.wilhelmus@amsterdamumc.nl).